Japanese Biotech Startups

Japanese biotech startups are advancing healthcare and life sciences through research-driven innovation, specialized scientific expertise and commercialization-focused development. By translating emerging discoveries into practical therapies, platforms and solutions, they help strengthen Japan’s biotech ecosystem while addressing evolving needs across medicine, diagnostics and advanced life sciences.

Top Solutions
Spiber: Engineering Protein Materials for Scalable Industrial Adoption
Spiber
Spiber: Engineering Protein Materials for Scalable Industrial Adoption
Maya Kawana, Director
Synthetic fibers and animal-derived textiles continue to place pressure on supply chains, land usage and resource consumption. Spiber entered this environment with a biotechnology platform centered on Brewed Protein™ materials, produced through microbial fermentation using plant-based inputs. The company focuses on translating protein science into commercially usable fibers, films and resins for industrial manufacturing.

Its development process combines genetic design, fermentation and material processing into one connected production framework. Instead of limiting its work to laboratory experimentation, it built a manufacturing path capable of producing materials at industrial scale. That approach positioned Spiber beyond the pilot-stage limitations that often slow biomaterial ventures.
Expanding Protein Engineering Into Commercial Materials

Brewed Protein™ fibers are designed to reproduce qualities commonly associated with silk, wool and cashmere while reducing environmental burden during production. Internal lifecycle assessments highlighted reductions in greenhouse gas emissions, land use and water consumption compared with conventional animal fibers. The material also demonstrated biodegradability under marine conditions within six months in testing.

Spiber structured its platform around repeatable manufacturing steps. Natural protein data is collected and analyzed, DNA sequences are designed for targeted material traits and microorganisms produce proteins through fermentation. Those proteins are then processed into fibers, films or resin-like forms suitable for industrial applications. Continuous feedback between these stages accelerates material refinement and product development.

Commercial usage has expanded steadily through partnerships across the textile ecosystem. More than 40 brands and over 80 textile and yarn manufacturers have worked with Brewed Protein™ materials. Applications range from knitwear and outerwear to tailored garments and accessories, allowing manufacturers to test the material across different production environments and product categories.

Building Industrial Pathways Beyond Prototype Development

Scale became a central focus once Spiber moved beyond experimental batches. Its Thailand production facility enabled larger manufacturing volumes, allowing the material to enter broader commercial channels. Partnerships with firms such as ADM strengthened fermentation and supply chain capacity while supporting expansion into international markets.
Read more
State of Industry

Japanese Biotech Startups Expand Their Global Healthcare Presence

Japanese biotech startups are entering a new phase of commercial and scientific growth. Long recognized for strengths in pharmaceuticals, regenerative medicine and academic research, Japan is now producing a broader pipeline of biotechnology companies focused on next-generation therapeutics, gene editing and AI-supported drug discovery.

The sector is gaining attention from pharmaceutical companies, investors and healthcare systems looking for innovation beyond traditional biotechnology hubs in the US and Europe. Startups across Japan are increasingly participating in international licensing agreements, strategic partnerships and cross-border clinical research programs.

Biotechnology in Japan has historically been shaped by large pharmaceutical companies and university-led research institutions. Recent market changes have created stronger conditions for startup growth, particularly in regenerative medicine, oncology research and precision healthcare.

Government policy has played an important role in accelerating the sector. Japan introduced regulatory reforms for regenerative medicine earlier than many global markets, allowing conditional and time-limited approval pathways for certain therapies. These measures helped position the country as an important center for stem cell research and cell therapy development.

Academic institutions continue to influence market growth. Universities and research centers in Tokyo, Osaka and Kyoto generate intellectual property and scientific talent that support the formation of biotechnology companies. Collaboration between startups and established pharmaceutical companies has also become more common.

Regenerative medicine remains one of Japan’s strongest biotechnology segments. Research linked to induced pluripotent stem cells, commonly known as iPS cells, continues to shape the country’s scientific reputation. Japanese researchers were among the earliest leaders in the field, helping establish long-term investment interest in cell-based therapies.

Drug discovery is another area experiencing rapid development. Japanese biotech startups are increasingly using artificial intelligence, computational biology and genomic analysis to accelerate therapeutic research. Pharmaceutical companies are paying closer attention to startups that can shorten drug development timelines and improve candidate selection.

Cancer treatment continues to attract substantial investment across the market. Biotechnology firms are expanding research into immunotherapy, targeted therapeutics and personalized treatment approaches. Demand for more precise therapies is increasing as healthcare systems place greater emphasis on patient-specific treatment models.

Rare disease treatment is also becoming a larger focus area. Smaller biotechnology companies are exploring therapies for conditions often overlooked within conventional pharmaceutical pipelines. Advances in gene editing and molecular diagnostics are supporting this shift.

Japan’s aging population is influencing market priorities as well. Healthcare providers and policymakers are increasingly interested in treatments related to chronic disease management, regenerative medicine and age-related conditions. Startups focused on neurological disorders, tissue repair and longevity research are attracting stronger investor attention.

Investment activity across Japanese biotechnology has improved during recent years despite volatility in global venture markets. International investors are showing greater interest in Japanese startups because of the country’s scientific expertise, intellectual property base and regulatory support for advanced medicine.

Manufacturing and commercial scale remain major challenges for many emerging companies. Biotechnology production requires substantial capital, regulatory compliance and specialized infrastructure. Smaller firms often face pressure when transitioning from research-stage development to broader commercial delivery.

Access to global markets is another challenge. Japanese biotech startups have historically focused heavily on domestic partnerships and local research ecosystems. Many newer companies are now pursuing international expansion, particularly across North America and Europe.

Talent competition is intensifying as the market expands. Biotechnology firms require expertise across molecular biology, clinical research, regulatory affairs and advanced manufacturing. Competition for highly specialized talent is increasing between startups, pharmaceutical companies and international research organizations.

The sector also faces pressure around funding continuity. Biotechnology development cycles are lengthy and capital-intensive. Startups often need multiple funding rounds before reaching commercial milestones or regulatory approval stages.

Partnerships are becoming increasingly important in response to these pressures. Pharmaceutical companies are collaborating with startups to strengthen research pipelines while emerging biotechnology firms gain access to manufacturing capabilities, clinical networks and global distribution channels.

Mature biotech startups are increasingly distinguished by scientific validation, intellectual property strength and clinical development progress rather than early-stage research potential alone. Investors and pharmaceutical partners are placing greater emphasis on scalable platforms and commercial viability.

Artificial intelligence is expected to influence the next phase of the market. Japanese biotechnology firms are exploring machine learning models for molecular analysis, clinical trial optimization and drug target identification. These technologies may help reduce development timelines and research costs over time.

Japan’s biotechnology sector is also expected to benefit from broader healthcare digitization and precision medicine initiatives. Genomic data, personalized treatment models and advanced diagnostics are becoming increasingly connected within healthcare research ecosystems.

Japanese biotech startups are no longer viewed solely as regional innovators. The sector is becoming a more visible contributor to global healthcare research, particularly in regenerative medicine, precision therapeutics and advanced drug discovery.

Healthcare organizations, investors and pharmaceutical companies evaluating Japanese biotech startups in 2026 are focusing on more than scientific novelty alone. Clinical progress, regulatory strategy, manufacturing readiness and global partnership potential are becoming equally important factors in a market moving steadily toward international expansion.

Read more
Leadership Perspective
Promising Signs for a Resurgent Tech Ecosystem in Japan
White Star Capital
Promising Signs for a Resurgent Tech Ecosystem in Japan
Shun Nagao, Venture Partner

Japan’s tech sector has a lot going for it, a tech-savvy population, high internet penetration, and a thriving set of desirable cities. Yet, the last decade of technology growth in Japan has been limited. Coinciding with our tenth investment in Asia, and our first in Japan, White Star Capital has taken a closer look at how the Japanese tech sector and VC landscape is beginning to show promising signs of fresh growth.

What has changed?

A lot has changed since we produced our last report in 2018. However, despite some macro global concerns, we remain bullish about Japan in the long term. VC funding has accelerated in the last few years, triggering a surge in valuations across the country. As of the end of 2022, Japan’s tech sector has twelve unicorns.

Total capital invested in Japan’s startup ecosystem reached a record-high of $6.3 billion in 2021, after a slight drop in 2020. In contrast, to deal value, the number of deals has declined since 2018, indicating a fall in the number of early-stage startups, but promising signs of growth for Japan’s scaleups.

Trending sectors and verticals

SaaS, AI & machine learning, and mobile were the three hottest verticals in terms of VC funding in 2021-2022 YTD. The same three verticals also led the way in terms of deal count, with SaaS at 459, AI and machine learning at 331, and mobile at 226. While the top five fastest-growing sectors in 2021 in terms of funding were content curation, space, logistics, food tech, and Biotechnology. Sectors we expect to see continued growth in over the coming years.

The macro perspective

From a macro-perspective Japan has been somewhat at a stand-still for the past three decades, due to continued deflationary pressure, challenging demographics, the rise of competitive neighbors, and chronic resistance to change. However, under the hood, there have been promising technology and innovation trends, towed by budding entrepreneurs, which are now blooming. International technology investors are no longer passing over this market, as can be seen by the large early-stage deals participation in 2020.

"SaaS, AI & machine learning, and mobile were the three hottest verticals in terms of VC funding in 2021-2022 YTD."

In addition, the current government administration led by Prime Minister Fumio Kishida has announced multiple initiatives to support Japan’s startup ecosystem since assuming office in October 2021, including increasing the budget related to startup investments to ¥10 trillion ($7.7 billion) by 2027, as well as launching a ministerial post to promote startups. A five-year plan has also been formulated towards the end of 2022 which includes a roadmap to increase the number of startups by 10x over the next five years.

Looking Toward the Future

Whilst there is much focus on Japan’s low growth and aging population, Japan remains the world’s third-largest economy and has a highly attractive domestic market that international tech players are increasingly looking to target. We see a new generation of entrepreneurs coming out of these companies that drive the start-up ecosystem going forward. In particular, Japan is quickly emerging as a global leader in artificial intelligence research and business applications. The surge in unicorns that leverage this technology at their core is evidence of Japan’s increasing global presence in this field.

We continue to have a strong belief that the market is on an upward trajectory and that we will see great entrepreneurs create meaningful and impactful businesses extending beyond national borders.

Read more

Japanese Biotech Startups FAQ

Q1
What Do Top Biostimulant Companies Do for Agriculture?
Top Biostimulant Companies develop products that support plant growth, crop resilience and nutrient efficiency without functioning as conventional fertilizers or pesticides. Their offerings may include microbial formulations, seaweed extracts, humic substances, amino acids or other biologically active inputs. For growers, agribusinesses and crop advisers, these companies help address soil health, stress tolerance and yield consistency. In a Top Companies editorial context, the category highlights providers shaping how modern agriculture combines productivity goals with more sustainable input strategies.
Q2
Why Do Biostimulant Providers Matter Now?
Top Biostimulant Companies matter because agriculture faces pressure to produce more while using resources more carefully. Climate variability, soil degradation, water stress and changing residue expectations are pushing growers to look beyond traditional crop inputs. Biostimulant providers can support this shift by improving nutrient uptake, root development and plant performance under stress. The category is especially relevant for agribusinesses looking for practical tools that fit into integrated crop nutrition, regenerative farming and precision agriculture programs.
Q3
How Are Leading Biostimulant Companies Typically Evaluated?
Evaluation usually considers product science, field validation, formulation quality, agronomic relevance and consistency across crops or growing conditions. Strong companies tend to explain how their products work, where they perform best and how they should be integrated with existing crop programs. Reviewers may also look at regulatory readiness, distribution strength, technical support and farmer education. For a Top Companies list, the focus is not only on market visibility but on whether a company brings credible value to growers, retailers, cooperatives and agricultural decision-makers.
Q4
What Value Do Biostimulant Solutions Create for Growers and Agribusinesses?
Biostimulant solutions can create value by helping crops use nutrients more efficiently, tolerate abiotic stress and maintain performance during difficult growing periods. They may also support soil biology and complement broader sustainability targets. Top Biostimulant Companies are often valued for turning biological complexity into products that are practical for farms, distributors and advisers to apply. The strongest providers connect agronomic benefit with ease of use, clear application guidance and measurable relevance across real field conditions.
Q5
How Does Innovation Shape the Biostimulant Market?
Innovation in the biostimulant market increasingly depends on better biological understanding, stronger formulation methods and more precise crop-use recommendations. Advances in microbial science, fermentation, metabolite research, seed treatment and digital agronomy are helping providers move from broad claims toward targeted performance. Expertise also matters because biological products can be sensitive to crop type, timing, soil conditions and climate. Companies that combine research discipline with practical agronomy are better positioned to earn trust in a category where credibility is essential.
Q6
What Should Agribusinesses Prioritize When Comparing Biostimulant Companies?
Agribusinesses should compare product evidence, crop fit, technical service, regulatory clarity, supply reliability and compatibility with existing nutrition or crop protection programs. They should also assess whether a provider communicates realistic expectations rather than overstating results. Top Biostimulant Companies should help growers understand when, where and why a product is likely to add value. The best choice is usually a partner with sound science, field-level experience and a service model that supports long-term adoption rather than one-time product trials.